Study: Optimal treatment duration for MRSA-related pneumonia

October 19, 2012

The national practice guideline for treating MRSA-related pneumonia is seven to 21 days. A Henry Ford Hospital study found that effective treatment can be done in half the time.

Researchers found that 40 percent of patients were treated for eight to 13 days on a therapy of the antibiotics vancomycin or linezolid, and had the highest survival rate.

The Henry Ford study is believed to be the first to evaluate the length of treatment for MRSA-related pneumonia.

The study is being presented Friday at the annual Society of America meeting in San Diego.

"Based on our study, clinicians can effectively treat their patients within eight to 13 days, thus minimizing patients' exposure to antibiotics and their side effects," says Hadeel Zainah, M.D., a second-year Infectious Diseases fellow at Henry Ford and the study's lead author.

MRSA-related pneumonia is a respiratory illness that typically follows a bout of the flu. Symptoms include a cough, sore throat, head ache, shortness of breath, fever and chills.

In the , researchers evaluated the medical charts of 115 patients hospitalized with MRSA pneumonia. Patients received either or linezolid, or both.

Of the 115 patients, 32 died after 28 days. Other findings:

  • 27 percent of patients were treated for 14-20 days.
  • 13.9 percent of patients were treated for more than 20 days.
  • These treatment durations had lower than the eight to 13 days.
Researchers did not evaluate whether the treatment duration affected length of stay or whether one antibiotic fared better than the other.

Explore further: Antibiotic linezolid an effective option for treating patients with MRSA infection

Related Stories

Antibiotic linezolid an effective option for treating patients with MRSA infection

May 16, 2011
The antibiotic linezolid may be more effective than vancomycin in treating ventilated patients who develop methicillin-resistant Staphylococcus aureus (MRSA) pneumonia as a result of their ventilation, according to a study ...

Recommended for you

Groundbreaking investigative effort identifies gonorrhea vaccine candidates

September 19, 2017
Researchers at Oregon State University have identified a pair of proteins that show promise as the basis for a gonorrhea vaccine.

Snail fever progression linked to nitric oxide production

September 14, 2017
Bilharzia, caused by a parasitic worm found in freshwater called Schistosoma, infects around 200 million people globally and its advance can lead to death, especially in children in developing countries.

Systems analysis points to links between Toxoplasma infection and common brain diseases

September 13, 2017
More than 2 billion people - nearly one out of every three humans on earth, including about 60 million people in the United States - have a lifelong infection with the brain-dwelling parasite Toxoplasma gondii.

Study clears important hurdle toward developing an HIV vaccine

September 13, 2017
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation ...

As 'flesh-eating' Leishmania come closer, a vaccine against them does, too

September 13, 2017
Parasites that ulcerate the skin, can disfigure the face, and may fatally mutilate its victim's internal organs are creeping closer to the southern edges of the United States.

Promising clinical trial results could give doctors a new tool against drug-resistant strains of malaria parasite

September 13, 2017
Tulane University researchers have developed a new drug that is effective against non-severe cases of malaria, according to results from an FDA-supervised clinical trial published in the latest issue of The Lancet Infectious ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.